000			05931cam a2200481Ii 4500
988			_aSpringer_Medicine_2017
999			_c96097 _d96097 _x1
001			96097
003			ES-MaUEC
005			20230102112738.0
006			m o d
007			cr cnu|||unuuu
008			170601s2017 sz ob 001 0 eng d
020			_a3319484680
020			_a3319484702 _q(electronic bk.)
020			_a9783319484686
020			_a9783319484709 _q(electronic bk.)
020			_z9783319484686
040			_aN$T _cN$T _dEBLCP _dN$T _dGW5XE _dYDX _dAZU _dUPM _dOCLCF _dCOO _dOCLCQ _dVT2 _dUAB _dES-MaUEC _bspa
050		4	_aRC182.S4 _b2017 EB
066			_c(S
245	0	0	_aSepsis : _bdefinitions, pathophysiology and the challenge of bedside management _cNicholas S. Ward, Mitchell M. Levy, editors.
264		1	_aCham _bHumana Press _c2017.
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
490	0		_aRespiratory medicine _x2197-7372
500			_aSpringerLink
504			_aIncluye referencias bibliográficas e índice
505	0		_6880-01 _aPreface; Contents; Contributors; Part I; Chapter 1: Introduction; References; Chapter 2: Sepsis Definitions; Introduction; History of the Definition of Sepsis; Origins of the Definition of Sepsis; 1991 International Consensus Conference; 2001 International Consensus Conference; 2010 Merinoff Symposium; 2016 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3); Difficulties in Defining Sepsis; Shortcomings of the SIRS Criteria; Staging of Sepsis; Problems with in Early Stage Sepsis; Adoption of the Term "Septic" in Medical Culture.
505	8		_aAnti-Inflammatory Cytokines IL-10; Chemotactic Cytokines; Complement and Coagulation Cascades; Antimicrobial Peptides; Lipid Mediators; Prostanoids and Leukotriene; Reactive Oxygen Species (ROSs), Reactive Nitrogen Species (RNSs), and Nitric Oxide (NO); Immune Resolution of Sepsis; Summary; References; Chapter 5: Sepsis-Induced Immune Suppression; Introduction; Cytokines in Sepsis-Induced Immune Suppression; The Role of Immune Cells in Sepsis-Induced Immunosuppression; Impaired Immune Cell Function and Programmed Cell Death in Sepsis; Neutrophils; Antigen Presenting Cells.
505	8		_aDefining Sepsis Through Clinical or Administrative Data Coding; Criteria; Angus Criteria; Martin Criteria; Comparison of Different Methods; Trends in Mortality and Disability in Sepsis; Future Directions; Conclusions; References; Chapter 3: Epidemiology of Sepsis: Current Data and Predictions for the Future; Introduction; Incidence and Outcome of Sepsis; Global Cohorts; The Cost of Sepsis; Long-Term Outcomes; Demographic and Genetic Factors; Gender; Race; Socioeconomic Status; Biological Factors; Comorbidities; Malignancy; HIV; Obesity; Diabetes.
520	3		_aThis book is designed to provide a comprehensive and state-of-the-art resource for clinicians who care for patients with sepsis and research scientist alike, . Patients with severe sepsis requiring ICU admission have very high rates of ICU and overall hospital mortality, with estimates ranging from 18 to 50%. Risk factors for death from sepsis include underlying illness, increased age, and multi-system organ failure. This is compounded by the significant variation in the management of early severe sepsis. Care of these patients and clinical conditions can be quite complex, and materials are collected from the most current, evidence-based resources. Book sections have been structured to review the overall definitions and epidemiology of sepsis as well as current insights into the pathophysiology of sepsis. This review summarizes the evidence for the international consensus guidelines for the identification and management of sepsis. The latter part of this book reviews emerging concepts and approaches in the diagnosis and management of sepsis that may significantly reduce mortality in the future. Sepsis: Pathophysiology, Definitions and the Challenge of Bedside Management represents a collaboration between authors drawn from a variety of disciplines and contributions from basic scientists and highly recognized clinical opinion leaders with expertise in clinical trials.
650		7	_aSepticemia _2embne _9143089 _0comprobar BNE19901032950
700	1		_aLevy, Mitchell M., _d1950- _eeditior.
700	1		_aWard, Nick, _d1964- _eeditior.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-48470-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880	8		_6505-00/(S _aDendritic Cells Monocytes/Macrophages; Lymphocytes; Natural Killer Cells; CD4+ TH Cells; γδ T Cells; Regulatory T Cells; Predicting Clinical Outcomes with Biomarkers of Sepsis-ƯInduced Immunosuppression; Potential Therapeutic Interventions in Sepsis-Induced Immune Suppression; Interleukin-10; Interleukin 7 (IL-7); Interleukin 15 (IL-15); Programmed Cell Death Receptor-1 (PD-1) and Programmed Cell Death Ligand-1 (PD-L1); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); Interferon-Gamma; Conclusion; References; Chapter 6: Molecular Targets for Therapy; Introduction.
880	8		_6505-01/(S _aEtiology and Source of Infection Conclusions; References; Part II; Chapter 4: Overview of the Molecular Pathways and Mediators of Sepsis; Background; Introduction to Innate and Adaptive Immune Responses; Innate Immunity; Adaptive Immunity; Cells Involved in Immune Response in Sepsis; Monocytes and Macrophages; Dendritic Cells; Neutrophils; Natural Killer Cells; Other Innate Regulatory Cells; CD4+/CD8+ T and B Lymphocyte Cells; Alterations in Sepsis; Inflammatory Cytokines and Chemokines; TNF-α and IL-1; MIF and HMGB-1; Future Diagnostic Inflammatory Markers.
942			_2lcc _cLE
998			_b02/2018 _dz _e- _zSI